精神分裂症复发预防的心理社会与心理干预:系统综述与网络Meta分析
家庭干预、复发预防项目、认知行为疗法、家庭心理教育、整合干预和患者心理教育在1年时均优于常规治疗,其中家庭干预、家庭心理教育和认知行为疗法证据最稳健。
要点
- 家庭干预、家庭心理教育和认知行为疗法应作为长期治疗中优先考虑的心理社会干预。
- 证据确定性从中等到极低,解读结果需谨慎。
核心结论
- 家庭干预、家庭心理教育和认知行为疗法在减少精神分裂症复发风险方面具有稳健获益,应作为长期治疗中优先考虑的心理社会干预。
研究设计与样本
- 系统综述与网络Meta分析,检索EMBASE、MEDLINE、PsycINFO、BIOSIS、Cochrane Library、WHO ICTRP和ClinicalTrials.gov至2020年1月20日,PubMed至2020年4月14日。
- 纳入成人精神分裂症或相关障碍的开放与盲法随机对照试验,排除所有患者均为急性期、共病躯体或精神障碍、或前驱期/精神病风险的研究。
- 采用随机效应网络Meta分析计算OR或SMD及95%CI,方案注册于PROSPERO(CRD42019147884)。
主要发现
- 估计值置信度从中等到极低不等。
- 未发现发表偏倚迹象。
关键数值与推荐
- 主要结局为采用操作性标准或精神科住院评估的复发。
- 上述6种干预在1年时减少复发优于常规治疗的OR及95%CI见findings。
临床怎么用
- 在精神分裂症长期治疗中,应优先考虑家庭干预、家庭心理教育和认知行为疗法以预防复发。
局限性
- 证据确定性从中等到极低不等。
- 缺乏种族数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Many psychosocial and psychological interventions are used in patients with schizophrenia, but their comparative efficacy in the prevention of relapse is not known. We aimed to evaluate the efficacy, acceptability, and tolerability of psychosocial and psychological interventions for relapse prevention in schizophrenia. METHODS: To conduct this systematic review and network meta-analysis we searched for published and unpublished randomised controlled trials that investigated psychosocial or psychological interventions aimed at preventing relapse in patients with schizophrenia. We searched EMBASE, MEDLINE, PsycINFO, BIOSIS, Cochrane Library, WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov up to Jan 20, 2020, and searched PubMed up to April 14, 2020. We included open and masked studies done in adults with schizophrenia or related disorders. We excluded studies in which all patients were acutely ill, had a concomitant medical or psychiatric disorder, or were prodromal or "at risk of psychosis". Study selection and data extraction were done by two reviewers independently based on published and unpublished reports, and by contacting study authors. Data were extracted about efficacy, tolerability, and acceptability of the interventions; potential effect moderators; and study quality and characteristics. The primary outcome was relapse measured with operationalised criteria or psychiatric hospital admissions. We did random-effects network meta-analysis to calculate odds ratios (ORs) or standardised mean differences (SMDs) with 95% CIs. The study protocol was registered with PROSPERO, CRD42019147884. FINDINGS: We identified 27 765 studies through the database search and 330 through references of previous reviews and studies. We screened 28 000 records after duplicates were removed. 24 406 records were excluded by title and abstract screening and 3594 full-text articles were assessed for eligibility. 3350 articles were then excluded for a variety of reasons, and 244 full-text articles corresponding to 85 studies were included in the qualitative synthesis. Of these, 72 studies with 10 364 participants (3939 females and 5716 males with sex indicated) were included in the network meta-analysis. The randomised controlled trials included compared 20 psychological interventions given mainly as add-on to antipsychotics. Ethnicity data were not available. Family interventions (OR 0·35, 95% CI 0·24-0·52), relapse prevention programmes (OR 0·33, 0·14-0·79), cognitive behavioural therapy (OR 0·45, 0·27-0·75), family psychoeducation (OR 0·56, 0·39-0·82), integrated interventions (OR 0·62, 0·44-0·87), and patient psychoeducation (OR 0·63, 0·42-0·94) reduced relapse more than treatment as usual at 1 year. The confidence in the estimates ranged from moderate to very low. We found no indication of publication bias. INTERPRETATION: We found robust benefits in reducing the risk of relapse for family interventions, family psychoeducation, and cognitive behavioral therapy. These treatments should be the first psychosocial interventions to be considered in the long-term treatment for patients with schizophrenia. FUNDING: German Ministry for Education and Research.
引用
- Bighelli I, Rodolico A, García-Mieres H, et al. Psychosocial and psychological interventions for relapse prevention in schizophrenia: a systematic review and network meta-analysis. Lancet Psychiatry. 2021. PMID: 34653393. doi:10.1016/S2215-0366(21)00243-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。